Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
INTRODUCTION

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; first referred to as 2019-nCoV) emerged in Wuhan, China in late December 2019, and resulted in the Coronavirus disease-2019 (COVID-19) pandemic.1,2 Although the primary organ involved in COVID-19 appears to be the lungs, cardiac involvement can also occur. Acute myocardial injury has been linked to worse prognosis and higher mortality in patients with COVID-19.3–7

The definition of acute myocardial injury is nonspecific and differed in various studies. In most studies, acute cardiac injury was defined as cardiac troponin value above the 99th percentile upper reference limit (URL) or the occurrence of new abnormalities in electrocardiography and echocardiography.4,8 The frequency of myocardial injury has been reported to range from 7% to 28% among hospitalized patients with COVID-19.3,5,8–10 However, data on the frequency of myocardial damage in outpatient setting is lacking.

According to the Fourth Universal Definition of Myocardial Infarction (2018), the 99th percentile URL is considered as the decision level for the diagnosis of myocardial injury11; however, this cutoff level includes all conditions causing “myocardial cell death” with subsequent elevation in cardiac troponin levels. Based on the data from case series and reports, putative causes of myocardial injury include:

**Ischemic causes:**

- Acute coronary syndrome caused by either plaque instability and rupture (type I myocardial infarction) or demand ischemia (type II myocardial infarction)
- Endotheliitis12 leading to endothelial dysfunction and microvascular damage

**Nonischemic causes:**

- Hypoxic injury
- Stress cardiomyopathy (i.e., takotsubo cardiomyopathy)13,14
- Profound systemic inflammatory response/cytokine storm leading to myocardial suppression
- Right heart failure15–17 (i.e., acute cor pulmonale), may result from pulmonary thromboembolism, pulmonary hypertension caused by ARDS (due to hypoxic vasoconstriction, vascular remodeling, external compression of the vasculature by edema or fibrosis, and reduced pulmonary compliance), and high-pressure mechanical ventilation

SARS-CoV-2 uses transmembrane ACE2 receptors to enter the host cells. In addition to type-2 pneumocytes,
the ACE2 receptors are expressed on cardiac myocytes, endothelial cells, and pericytes.\textsuperscript{18,19} This might also contribute to the cardiac damage in SARS-CoV-2 infection, though the exact pathophysiologic mechanisms are still unclear.

Key cardiovascular manifestation of COVID-19 and suggested pathophysiologic mechanisms are summarized in Fig. 41.1.\textsuperscript{20}

**Key Points**

- Although the clinical presentation of myocarditis has been described in a few case reports in patients with COVID-19,\textsuperscript{21,22} viral myocarditis caused by direct invasion of SARS-CoV-2 to myocardial tissue has not been definitively confirmed by histologic examinations and viral genome assays.
- Despite considerable incidence and prognostic implications of acute cardiac injury in hospitalized patients with COVID-19, there is insufficient evidence to recommend routine measurement of cardiac troponin to screen for acute myocardial injury in all COVID-19 patients.
- However, patients with history of prior coronary artery disease (CAD), structural heart disease, diabetes mellitus, hypertension, and chronic kidney disease tend to have more severe COVID-19 infection; and should be closely monitored for the occurrence of acute myocardial injury.

**DIAGNOSTIC APPROACH TO PATIENTS WITH ACUTE CARDIAC INJURY**

Cardiac injury symptoms are nonspecific in COVID-19 and patients mostly present with the typical symptoms of SARS-CoV-2 infection, including fever, cough, dyspnea, or fatigue and a minority present with anginal chest pain and palpitations. A new-onset and/or unexplained dyspnea, orthopnea, peripheral edema, and jugular venous distension should raise clinical suspicious for cardiac involvement in patients with severe COVID-19 infection.

In clinically suspected patients, the diagnostic approach should include the following.

**Electrocardiogram**

- A 12-lead electrocardiogram (ECG) should be obtained initially in all patients with suspected myocardial damage. The most common ECG abnormality reported in patients with acute cardiac injury was ST-segment elevation or depression, T-wave depression and inversion, and Q waves. The QT interval (and corrected QT interval) should also be assessed, in particular in patients on QT-prolonging therapies.
- Initial ECG may provide clues to specific diagnoses, which require a change in management.
- QT prolongation of >500 ms or ventricular tachycardia in patients receiving certain medications (including chloroquine, hydroxychloroquine, lopinavir–ritonavir, azithromycin, etc.) may result in early discontinuation and replacement of the responsible medication.
- New pathologic Q waves, ST-T changes, or arrhythmia would mandate further cardiac assessments such as echocardiography.
- Various tachy- or bradyarrhythmia would require close electrolyte assessments, QT measurement, inotropic/vasopressor change, or proper therapies (antiarrhythmics/cardioversion).

**Routine Laboratory Tests**

- A complete blood count (with differential), blood glucose, blood urea nitrogen, creatinine, serum electrolytes, and liver function tests should be assessed in all patients.

**Chest X-ray**

- Although bilateral chest infiltration from the underlying pneumonia and ARDS from COVID-19 infection may obscure abnormalities caused by cardiac dysfunction, a CXR may help in the detection of cardiomegaly and pleural effusions.

**Cardiac Troponins**

- A cardiac troponin value above the 99th percentile upper reference limit is indicative of acute myocardial injury.\textsuperscript{11} Since an elevated troponin level in patients with COVID-19 is nonspecific and multifactorial, the results should be interpreted based on the clinical presentation, ECG findings, and echocardiographic examination.

**Natriuretic Peptides (BNP or NT-proBNP)**

- Natriuretic peptides are mainly released from the heart in response to increased myocardial wall stress. Several studies have demonstrated elevated BNP or NT-proBNP levels in COVID-19 patients, and an elevated NT-proBNP level has been associated with worse outcomes in patients with severe COVID-19.\textsuperscript{23,24} However, it should be noted that elevated NT-proBNP level has been reported in patients with acute lung injury and acute respiratory distress syndrome from other causes\textsuperscript{25–30} even in the absence of clinical findings of heart failure; therefore, an elevated NT-proBNP level should be interpreted based on the whole clinical presentation.
FIG. 41.1 For figure Legend see next page
Currently, there is insufficient evidence to recommend routine echocardiography for all COVID-19 patients with suspected cardiac damage. Considering the limitations in personal protective equipment and the importance of social distancing, the echocardiographic examination can be tailored to the presentation of each individual patient.

In selected cases, point-of-care ultrasonography (POCUS) and focused cardiac ultrasound study (FoCUS) could help in detecting gross abnormalities in cardiac structure and/or function. These bedside options may also be performed by the trained non-cardiologists who might already be in the room with these patients, thereby reducing the risk of cardiologists’ exposure to the virus.

CompliCations of CardiC InJury in Covid-19

Arrhythmias and Conduction Abnormalities

Although no specific arrhythmia has been linked to SARS-CoV-2 infection, both brady- and tachyarrhythmias, as well as sudden cardiac death have been reported in patients with COVID-19. Infection of the respiratory tract, particularly of type 2 pneumocytes, by SARS-CoV-2 is manifested by the progression of systemic inflammation and immune cell overactivation, leading to a “cytokine storm,” which results in an elevated level of cytokines such as IL-6, IL-7, IL-22, and CXCL10. Subsequently, it is possible that activated T cells and macrophages may infiltrate infected myocardium, resulting in the development of fulminant myocarditis and severe cardiac damage. This process could be further intensified by the cytokine storm. Similarly, the viral invasion could cause cardiac myocyte damage directly leading to myocardial dysfunction and contribute to the development of arrhythmia. (From Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666–1687; with permission.)

In patients with COVID-19, both de novo acute heart failure and acute decompensation of chronic heart failure might develop.

- In addition to heart failure with reduced ejection fraction (HFrEF), the occurrence of heart failure with preserved ejection fraction (HFpEF) should also be considered in COVID-19 patients. Acute myocardial injury, cytokine-induced inflammatory state, comorbidities such as hypertension, side effects of medications, and vigorous intravenous fluid administration might impair myocardial relaxation, in particular in the elderly and those with underlying diastolic dysfunction, resulting in acute heart failure.

- The presence of potential precipitating factors for acute decompensation of chronic heart failure should be carefully assessed and monitored in COVID-19 patients.

- Patients with previous history of chronic heart failure are recommended to continue their previous guideline-directed medical therapy, including
beta-blockers, ACE inhibitors or angiotensin II receptor antagonists, and mineralocorticoid receptor antagonists. When administering intravenous fluids to these patients, attempt should be done to avoid both volume overload and circulatory failure. For the management of fever, nonsteroidal anti-inflammatory drugs (NSAIDs) should be used with caution in these patients, considering their potential effect on water and sodium retention; thus, acetaminophen may be generally preferred in these patients.

Cardiogenic Shock
In patients with COVID-19, cardiogenic shock may be caused by:
- Acute decompensated heart failure
- Myocardial infarction
- Myocarditis
- Sustained refractory arrhythmia

In critically ill patients with COVID-19, a combination of cardiogenic shock and septic shock (mixed shock) may contribute to hemodynamic deterioration and impaired end-organ perfusion.

THROMBOSIS IN THE COVID-19 OUTBREAK
Since the early report from China, an unusual increased coagulopathy has been reported in COVID-19 population. In several population-based studies, non-survived population had significantly higher levels of D-dimer and fibrin degradation products and longer prothrombin and activated partial thromboplastin times (aPTT), which also confirmed an important prognostic role for the coagulopathy. Initially, the nature of this coagulopathy was related to the accompanied septic shock and disseminated intravascular coagulation (DIC). In one of the early reports, Tang et al. observed that DIC occurred in 71.4% of the non-survivors vs 0.6% of the survivors during hospitalization. However, as our knowledge grew, it became more apparent that a direct viral impact on the coagulation cascade may also play a role. For instance, in a report by Klok et al., none of the ICU patients with thrombotic complication developed DIC.

Venous Thromboembolism
The described coagulopathy, along with prolonged bed rest and concomitant therapeutic regimen, increase the risk of thrombotic events in COVID-19. Depending on the screening methods, investigation sites (wards vs ICUs) and the use of thromboprophylaxis, incidence of thrombotic events varies across studies between 7% and 85%. Klok et al. observed a 31% (95% CI: 20%–41%) incidence of thrombotic complications in three academic/teaching hospitals in the Netherlands, the majority of which were venous thromboembolism (VTE). High incidence (20.6%) of pulmonary embolism has also been reported by Poissy et al. at least two times higher than previous year during the same time interval. In a report by Middeldorp et al., the incidence of VTE in ICU was significantly higher than ward [59% (95% CI: 42–72) vs 9.2% (95% CI: 2.6–21)]. In addition, several postmortem studies have frequently shown the presence of pulmonary micro- and macrothrombosis and deep vein thrombosis, at times as the cause of unexpected death.

It should be noted that diagnosis of VTE might be very challenging in patients hospitalized for COVID-19: the inapplicability of D-dimer, issues with transferring to imaging wards, and difficulties in optimal patient positioning have left the diagnostic process of considerable numbers of patients, particularly the sickest, incomplete. Although not definite, but some diagnostic measures like right ventricular enlargement/dysfunction in echocardiography or deep venous thrombosis in lower limb detected by ultrasound might be helpful toward the diagnosis of pulmonary embolism. There is a clear controversy on the treatment of patients without definite diagnosis (i.e., incomplete diagnosis), and intermediate to full-dose anticoagulation have been suggested by some experts. Other risk stratification tools (e.g., Caprini and IMPROVE) have also been suggested to be applied. The International Society on Thrombosis and Haemostasis (ISTH) has offered a liberal recommendation
suggesting the administration of LMWH in all patients hospitalized for COVID-19 (including those that are not critically ill) who do not have contraindications (platelet count ≤25,000/L or active bleeding). This routine approach might be justified by the high incidence of VTE (27%) observed in hospitalized COVID-19 patients. Of note, mechanical prophylaxis has been suggested for patients with contraindication for pharmacological prophylaxis.

Although the importance of VTE prophylaxis has been recognized since the early days of pandemic, it still seems to be overlooked. Wang et al. in their short report showed that more than 40% of the 1026 hospitalized patients with COVID-19 had a Padua Prediction Score ≥4 (i.e., high risk for VTE), yet only 7% received appropriate treatment.

REFERENCES
1. World Health Organization. Pneumonia of Unknown Cause—China; 2020. https://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en/. Published January 5, Accessed April 4, 2020.
2. WHO. WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19- -11-march-2020. Published March 11, Accessed April 4, 2020.
3. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–810.
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
5. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infection in Wuhan, China. JAMA. 2020;323:1061–1069.
6. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:811–818.
7. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
8. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
9. Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis. 2020;63:390–391.
10. Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648–1655.
11. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018;72(18):2231–2264.
12. Pons S, Fodil S, Azoulay E, Zafrani L. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care. 2020;24(1):353.
13. Giustino G, Croft LB, Oates CP, et al. Takotsubo cardiomyopathy in COVID-19. J Am Coll Cardiol. 2020;76(5):628–629.
14. Minhas AS, Scheel P, Garibaldi B, et al. Takotsubo syndrome in the setting of COVID-19 infection. JACC Case Rep. 2020;2:1321–1325.
15. Creel-Bulos C, Hockstein M, Amin N, Melhem S, Truong A, Sharifpour M. Acute cor pulmonale in critically ill patients with COVID-19. N Engl J Med. 2020;382(21):e70.
16. Argulian E, Sud K, Vogel B, et al. Right ventricular dilation in hospitalized patients with COVID-19 infection. JACC Cardiovasc Imaging. 2020;13:2459–2461.
17. Pagnesi M, Baldetti L, Beneduce A, et al. Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. Heart. 2020;106:1324–1331.
18. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097–1100.
19. Nicin L, Apblanap WT, Mellentin H, et al. Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. Eur Heart J. 2020;41(19):1804–1806.
20. Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666–1687.
21. Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020;45(3):230–232.
22. Inciardi RM, Lupi L, Zacccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:819–824.
23. Gao L, Jiang D, Wen XS, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020;21(1):83.
24. Han H, Xie L, Liu R, et al. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. J Med Virol. 2020. https://doi.org/10.1002/jmv.25809 [Epub ahead of print].
25. Lai CC, Sung MI, Ho CH, et al. The prognostic value of N-terminal pro-B-type natriuretic peptide in patients with acute respiratory distress syndrome. Sci Rep. 2017;7:44784.
26. Determann RM, Royakkers AA, Schaefers J, et al. Serum levels of N-terminal pro-B-type natriuretic peptide in mechanically ventilated critically ill patients—relation to tidal volume size and development of acute respiratory distress syndrome. BMC Pulm Med. 2013;13:42.
27. Park BH, Park MS, Kim YS, et al. Prognostic utility of changes in N-terminal pro-brain natriuretic peptide combined with sequential organ failure assessment
scores in patients with acute lung injury/acute respiratory distress syndrome concomitant with septic shock. Shock. 2011;36(2):109–114.

28. Park BH, Kim YS, Chang J, et al. N-terminal pro-brain natriuretic peptide as a marker of right ventricular dysfunction after open-lung approach in patients with acute lung injury/acute respiratory distress syndrome. J Crit Care. 2011;26(3):241–248.

29. Karmpaliotis D, Kirtane AJ, Rusi CP, et al. Diagnostic and prognostic utility of brain natriuretic peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. Chest. 2007;131(4):964–971.

30. Sun YZ, Gao YL, Yu QX, et al. Assessment of acute lung injury/acute respiratory distress syndrome using B-type brain natriuretic peptide. J Int Med Res. 2015;43(6):802–808.

31. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372–2374.

32. Bhatla A, Mayer MM, Adusumalli S, et al. COVID-19 and myocardial infarction: a missing link? JACC Heart Fail. 2020;8(6):1154–1163.

33. Moschini I, Loffi M, Regazzoni V, Di Tano G, Gherbesi E, Danzi GB. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection. Heart Rhythm. 2020;17:1439–1444.

34. Shao F, Xu S, Ma X, et al. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. Resuscitation. 2020;151:18–23.

35. Voisin O, Loc’h EL, Mahe A, et al. Acute QT interval modifications during hydroxychloroquine-azithromycin treatment in the context of COVID-19 infection. Mayo Clin Proc. 2020;95(8):1696–1700.

36. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020;383:2041–2052.

37. Moschini I, Loffi M, Regazzoni V, Di Tano G, Gherbesi E, Danzi GB. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection. Heart Rhythm. 2020. [https://doi.org/10.1016/j.hrthm.2020.01.016] [Epub ahead of print].

38. Baldi E, Sechi GM, Mare C, et al. Out-of-hospital cardiac arrest during the Covid-19 outbreak in Italy. N Engl J Med. 2020;383(5):496–498.

39. Lai PH, Lancet EA, Weiden MD, et al. Characteristics associated with out-of-hospital cardiac arrests and resuscitations during the novel coronavirus disease 2019 pandemic in New York City. JAMA Cardiol. 2020;5:1154–1163.

40. Mehra MR, Ruschitzka F. COVID-19 illness and heart failure: a missing link? JACC Heart Fail. 2020;8(6):512–514.

41. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847.

42. Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147.

43. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950–2973.

44. Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation. 2020;142:184–186.

45. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with COVID-19: CHEST guideline and expert panel report. Chest. 2020;158:1143–1163.

46. Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18:1995–2002.

47. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421–1424.

48. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–1098.

49. Lodigiani C, Iapichino G, Careno L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14.

50. Wichmann D, Sperhake JP, Lüttgertmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med. 2020;M20-2003.

51. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endotheliitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120–128.

52. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;75:2950–2973.

53. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;41:1858.

54. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094–1099.

55. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18:1023–1026.